Ventrus Biosciences Inc. (Nasdaq: VTUS) reported disappointing results from a Phase 3 trial of its anal fissure pain treatment Diltiazem Hydrochloride 2% Cream sending the stock price plummeting $2.77 to $1.61.
Ventrus Reports Disappointing Results
February 12, 2014 at 11:54 AM EST
